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Cyclo-oxygenase 2It has been 30 years since the first level one clinical trial demonstrated low intensity pulsed ultrasound
(LIPUS) could accelerate fracture repair. Since 1994 numerous investigations have been performed on the
effect of LIPUS. The majority of these studies have used the same signal parameters comprised of an
intensity of 30 mW/cm2 SATA, an ultrasound carrier frequency of 1.5 MHz, pulsed at 1 kHz with an expo-
sure time of 20 minutes per day. These studies show that a biological response is stimulated in the cell
which produces bioactive molecules. The production of these molecules, linked with observations
demonstrating the enhanced effects on mineralization by LIPUS, might be considered the general manner,
or mode, of how LIPUS stimulates fractures to heal.
We propose a mechanism for how the LIPUS signal can enhance fracture repair by combining the find-
ings of numerous studies. The LIPUS signal is transmitted through tissue to the bone, where cells translate
this mechanical signal to a biochemical response via integrin mechano-receptors. The cells enhance the
production of cyclo-oxygenese 2 (COX-2) which in turn stimulates molecules to enhance fracture repair.
The aim of this review is to present the state of the art data related to LIPUS effects and mechanism.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
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Fracture healing is a complex process. Clinically, it requires ade-
quate reduction of the displaced fracture and stabilization. The bio-
logical process consists of several distinct temporal phases. These
46 A. Harrison et al. / Ultrasonics 70 (2016) 45–52phases are the inflammatory phase with cell proliferation, the
chondrogenic phase with cartilage hypertrophy and angiogenesis,
and the osteogenic phase with replacement of cartilage with
woven bone and subsequent remodeling. During the fracture heal-
ing process, various cell types must interact and deliver adequate
and appropriate levels of inflammatory and bioactive molecules.
Despite the complexity, most fractures heal without a problem.
In the United States, over eight million fractures occur annually,
with a delayed or non-union rate of 5–10% [1].
Several risk factors are associated with impaired bone healing.
These factors include the presence of systemic disease, such as dia-
betes [2]; advanced age [3,4]; or external chemical factors, such as
alcohol abuse [5], smoking [6], or prescribed medications like
chronic steroid use or chemotherapeutics [7]. These risk factors
provide an ongoing clinical challenge for the treatment of fractures
in our aging, comorbid population.
Several biophysical agents have been proposed and analyzed as
therapeutic adjuncts to address this impaired bone healing pro-
cess. These adjuncts include pulsed electromagnetic fields, com-
bined magnetic fields, direct electrical current and low-intensity
pulsed ultrasound. The pulsed electromagnetic systems generate
asymmetric, quasirectangular electromagnetic pulses grouped in
bursts. Individual pulse duration is approximately 260 ls, burst
frequency is 15 Hz and the peak field strength is 20 mT. The non-
union effectiveness rate for patients using one of the pulsed elec-
tromagnetic system for an average of 7.1 hours per day was 80%
[8]. Another pulsed electromagnetic system demonstrated a non-
union success rate of 63.5% for treatment periods up to 10 hours
[9]. The external combined magnetic field device produces a static
20 lT magnetic field and a sinusoidal dynamic field at a frequency
of 76.6 Hz and amplitude of ±40 lT. Patients use the device for
30 minutes per day, providing a nonunion heal rate of 60.7% [10].
The implanted direct current stimulator delivers a 20 lA current
via a wire cathode continuously for 24 hours a day for at least
6 months, resulting in a long term nonunion success rate between
38.8% and 66.7% [11]. Low-intensity pulsed ultrasound (LIPUS) is
indicated for certain fresh fractures and the treatment of non-
unions. A 20 minute treatment time results in a 38% acceleration
of fresh fractures [12,13] and an 86% nonunion success rate [14].
This review discusses LIPUS exclusively. When defining low inten-
sity for LIPUS we will deal specifically with an intensity of 30 mW/
cm2 SATA (spatial average–temporal average) and a power of
117 mW delivered via an unfocussed ultrasound transducer with
an active area of 3.88 cm2, as measured by the radiation force bal-
ance method. The ultrasound carrier frequency is 1.5 MHz, pulsed
at 1 kHz. The ultrasound power is measured by the Ohmic Instru-
ments ultrasound power meter.
The use of low intensity ultrasound to accelerate the fracture
repair process in humans was first reported by Xavier and Duarte
in 1983 [15]. This success led to clinical trials in the United States
[12,13] and the 1994 approval of EXOGEN by the U.S. Food and
Drug Administration for the accelerated healing of certain fresh
fractures. The product was approved for the treatment of estab-
lished non-unions in 2000 [14,16]. All the LIPUS articles stated in
this review have used the clinically approved ultrasound signal.
Specifically, 1.5 MHz sinusoidal waves modulated in bursts of
200 ms at a repetition frequency of 1 kHz, and a spatial average–
temporal average intensity of 30 mW/cm2.
The positive effect of low-intensity pulsed ultrasound on the
acceleration of bone healing has been demonstrated in non-
clinical and clinical studies. Clinical studies have demonstrated sig-
nificant positive effect of LIPUS in the treatment of fresh fractures
[12,13] and non-unions [14,16,17]. The prospective, randomized,
multi-center, double-blind level I clinical studies investigating
LIPUS treatment of conservatively treated tibia [12] and distal
radius [13] both demonstrated 38% acceleration in fracture repaircompared to fractures treated with a placebo device (p < 0.0001),
as assessed radiographically and clinically by blinded physicians.
For nonunion fractures, the studies [14,16,17] included nonunion
fractures that would not otherwise have healed. The fractures were
at least 9 months old, with a minimum of 3 months since the last
intervention. The only treatment change was daily LIPUS use.
Gebauer et al. investigated the effect of LIPUS in 67 subjects,
demonstrating heal rates of 85% after 5.6 months [16], while Nolte
et al. studied 29 nonunions that resulted in an 86% heal rate in an
average time of 5.5 months [14]. Neither study reported any safety
issues.
The diffraction pattern of the ultrasound waves produced by a
piston transducer, such as the LIPUS transducer, has two character-
istic zones: the near field (close to the transducer) and the far field
(farther from the transducer). The interface between the near field
and far field is described by the equation:
Z ¼ a
2f
c
where Z is the near field length, a is the radius of the transducer
after the near field length, f is the frequency, and c is the speed of
sound in the medium [18]. The LIPUS transducer has a radius of
11 mm, emitting 1.5 MHz ultrasound wave and propagating in
average tissue at 1540 ms1 [19]. The computed value of Z is
118 mm. The ultrasound beam pattern measured in water using a
hydrophone shows rapidly changing intensity amplitude across
the beam in the near field (Z = 0 mm). The complexity (successive
axial maxima and minima) of the ultrasound field decreases as
the axial distance from the transducer increases. At Z = 60 mm
(mid-near field), the complexity of the beam decreases and forms
less maxima and minima. At Z = 118 mm (far field), the ultrasound
pressure wave is more uniform. For the experiments described in
this review, all the cell culture and in vivo experiments were per-
formed in the near field. This is contrary to recommendations to
place the in vitro cell culture within the far field where the pressure
levels and temporal variation of intensity are controlled [20]. How-
ever, placement within the near field more closely matches the clin-
ical situation as the majority of bones have little soft tissue
coverage. The deepest bone treated clinically is the femur. With
the far field starting at 118 mm, and assuming the femur is in the
center of the thigh, the circumference of a patient’s thigh would
need to be 74 cm (29 inches) before a femur would be receiving
ultrasound in the far field. Anthropometric data indicates that 95%
of Americans have a mid-thigh circumference of less than 75 cm
(29.5 inches) [21]. Therefore, application of the ultrasound coupled
to a petri dish or directly to a rodent’s limb provides a more clini-
cally relevant ultrasound field. In the in vivo studies, the animals
were sedated daily and the active or placebo transducer coupled
to the skin with ultrasound gel directly above the fracture, unless
otherwise stated. The in vivo models typically used either rats or
mice, with a closed femoral fracture first described by Bonnarens
and Einhorn [22]. This model is widely regarded as the standard
in vivo model for traumatic fractures. The phases of fracture healing
match those observed clinically, albeit on a shorter timescale. The
consistency of the fracture allows this in vivo model to be used to
investigate different interventions and mechanisms. The purpose
of this review is to provide our current understanding regarding
the mechanism and mode of action for LIPUS.
Routinely the literature states that ‘the mechanism of LIPUS has
yet to be elucidated’. We believe that there is evidence supporting
both a credible mode and a mechanism behind the LIPUS technol-
ogy. ‘Mode’ is described in dictionaries as ‘a way in which some-
thing occurs or is done’ [23]. Therefore the mode of action that
we propose for how LIPUS stimulates an enhanced healing process
to accelerate fracture repair can be seen as the stimulation of pro-
cesses and molecules that contribute to heal the fracture is related
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LIPUS achieves this is quite different from the mode. The dictionary
definition of ‘Mechanism’ is ‘the way in which something works or
is brought about’ [23]. This review will seek to investigate the
evidence for both the mode and mechanism behind the LIPUS tech-
nology, first by explaining the osteogenic action of LIPUS on frac-
ture repair, then by demonstrating the mechanism by evaluating
the LIPUS signal and how this is ‘interpreted’ by the cells to elicit
a healing response, using the best key evidence. This review is an
update of a previous review in this journal in 2008 to pull together
aspects of the biology to describe a mechanism of action [24]. Pre-
viously, LIPUS was believed to work equally in all phases of frac-
ture repair. This update provides more detailed evidence
supporting the impact on endochondral ossification and a clear
effect on bone resorption during healing. In addition, there is a
clear mechanistic link between integrin activation and COX2
upregulation.2. The mode of action of LIPUS in fracture repair
2.1. Effect of LIPUS in animal models of fracture repair
In order to understand the effect LIPUS has on fracture repair,
numerous pre-clinical models have been used to simulate the clin-
ical situation. One such experimental in vivo model was performed
treating fractures at different periods of repair. A rat closed femoral
fracture was created in both hind limbs with the right femur
exposed to LIPUS, and the left femur used as a control [25]. Rats
were divided into four groups according to timing and duration
of treatment. The animals in each group were treated with LIPUS
for 20 minutes per day as follows: LIPUS treatments were per-
formed in the Phase 1 group for 8 days, from day 1 to 8 after frac-
ture; in the Phase 2 group for 8 days, from day 9 to 16 after
fracture; in the Phase 3 group for 8 days, from day 17 to 24 after
fracture. The last group was treated from days 1 to 24, throughout
the healing process. The authors considered this to represent the
hematoma, soft callus and mineralization phases of fracture repair.
Animals were euthanized on day 25, and radiographs and torsional
biomechanical testing were used to assess fracture healing. The
maximal torque and stiffness in torsion of the fractured femur on
the LIPUS-treated side was significantly higher than that of the
contralateral control side in all groups (p < 0.01). This indicated
that even partial treatment with LIPUS during Phase 1, 2, or 3
improved the mechanical properties of the fracture callus; how-
ever, treatment throughout the 24 days was most effective
(p < 0.05). The histology presented in this study showed an acceler-
ation of endochondral ossification, in that the LIPUS-treated frac-
tures at day 25 resulted in much more bone formed than in
controls at the same time point. This observation of accelerated
endochondral ossification was reproduced in another in vivo study
using a closed transverse mid-diaphyseal femoral fracture also in
rats [26]. LIPUS was applied for 10 min daily, with the contralateral
control limb receiving an inactive transducer. The formation of the
new tissue after fracture was assessed by micro CT each week for
three weeks, with phasing thresholds which differentiated un-
mineralized tissue, less dense bone, calcified cartilage, and dense
or cortical bone. This technique provided further evidence of LIPUS
influencing the fracture cascade, including enhanced bone
formation in the fracture gap and enhanced resorption of the
‘old’ cortical bone. Using histology, this study also showed that
the number of osteoclasts was significantly increased in the
LIPUS-treated fractures compared with controls, which suggests
that LIPUS can influence the remodeling phase of fracture repair.
The stimulation of osteoclastic action has been hypothesized as
resulting from increased concentrations of ATP released byLIPUS-treated osteoblasts into culture medium which was associ-
ated with increased Receptor Activator of Nuclear Factor Kappa B
Ligand (RANKL) and decreased osteoprotegerin expression [27].
These data suggest, along with other studies [25,26,28], that the
most significant effect of LIPUS on fracture repair is on endochon-
dral ossification, the process of converting soft, cartilaginous callus
to hard, mineralized callus, increasing the mechanical stability of
the healing fracture. For an efficient process of endochondral ossi-
fication, it is accepted that the fracture site needs to be vascular-
ized similarly to that observed in growing bone [29].
2.2. Processes in accelerating endochondral remodeling by LIPUS
As seen in the preclinical models of fracture repair, LIPUS
enhances the process of endochondral ossification. One of the
key processes in endochondral remodeling is the increase in blood
vessels invading the fracture site. LIPUS has been shown to
increase key growth factors involved in the process of angiogene-
sis, the formation of new blood vessels. Vascular endothelial
growth factor (VEGF) is a growth factor that causes the formation
of new blood vessels [30]. An in vivo study investigated the effect
of LIPUS in a type 1 diabetes mellitus (DM) femoral fracture rat
model [31]. The number of blood vessels invading the fracture site
was assessed by measuring PECAM 1 levels. In the DM group the
density of blood vessels at the fracture site was significantly
reduced compared with normal control animals (p = 0.004). With
the addition of LIPUS, the DM animals had a significantly increased
blood vessel density compared with DM animals that had not
received LIPUS (p = 0.017), representing a 77.6% increase. This
effect was linked to significant increases in VEGF production in
LIPUS-treated fractures (p = 0.02).
The impact of LIPUS on the process of endochondral ossification
was clearly demonstrated in a mid-diaphysis femur fracture model
in aged mice [32]. At day 21 post-fracture in 8 week old mice, the
process of endochondral ossification was mostly complete. How-
ever, in aged, 40 week old mice, the fracture gap was still present
at 21 days post-fracture and the tissue that remained was cartilagi-
nous. The impact of age on the fracture repair process was dimin-
ished when the animals were treated with LIPUS. In the 40 week
old mice, radiographs showed that the fracture callus after 21 days
of LIPUS treatment was fully mineralized, leading to greater stabil-
ity of the fracture. The onset of endochondral ossification occurred
at the same time in the aged animals, but the overall process was
accelerated. In a parallel study of aged (1 year old) mice with bilat-
eral femur factures, X-rays and histology showed a similar phe-
nomenon. The mice were treated for 20 minutes per day with an
active or placebo ultrasound transducer. The period of endochon-
dral ossification in control aged mice was considerably longer com-
pared to the young mice, approximately 18 days compared to
7 days over the 28 day assessment period, with LIPUS shortening
the endochondral ossification in aged mice to approximately
11 days [33].
2.3. Osteogenic response of bone cells
In the process of endochondral ossification, the soft cartilagi-
nous or fibrous callus is converted to a calcified hard callus. In
order to complete this process, the cells in the local environment
produce factors that are associated with this conversion, such as
type X collagen, alkaline phosphatase and osteocalcin [34].
Two papers have demonstrated the enhanced stimulation of
osteogenic cells by LIPUS to drive endochondral ossification
[35,36]. These two independent research teams both took human
osteogenic cells and exposed them to LIPUS in vitro. In both sets
of experiments LIPUS was applied through the bottom of the cul-
ture plates for 20 minutes daily at 37 C and therefore the cells
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that is used clinically, described previously, was used in both sets
of experiments. Periosteal cells [35] and isolated cells from frac-
tures in the early phase of fracture repair [36] were used. The
results from these two studies were remarkably similar, with alka-
line phosphatase levels stimulated by LIPUS increasing with time
in culture over controls. In the case of the human periosteal cells
[35], 20 minutes exposure of LIPUS over 4 days resulted in a signif-
icant difference in alkaline phosphatase over controls of around
10% (p = 0.01) and 30% (p = 0.03) on days 2 and 4 respectively. With
progenitor cells isolated from the fracture hematoma [36], LIPUS
was applied daily for 20 minutes over 28 days. Alkaline phos-
phatase levels were significantly higher after 2, 4, 7, and 14 days
of LIPUS exposure (p < 0.05) over controls, showing a 20% increase
at day 2 through to, 40% on day 14; the same was true with regard
to osteocalcin secretion. Two master control genes of the osteo-
genic lineage, specifically cbfa-1/RUNX2 and osterix, were signifi-
cantly upregulated compared to controls (p < 0.05). The increase
in alkaline phosphatase levels, together with osteocalcin secretion
and expression of other osteoblast related genes demonstrated
that LIPUS promoted osteogenic differentiation of the progenitor
cells. The net result of this activity was to increase calcium deposi-
tion in the cultures of cells as seen by alizarin red staining. These
two studies show strikingly comparable results demonstrating
osteogenic differentiation in human cells in response to LIPUS.
These results also correspond to what is seen in animal models
and other pre-clinical studies, indicating that the responses initi-
ated in the human is similar to that seen in the animal. Increases
in bone specific genes was also observed in vivo following the
extraction of mRNA from the fracture callus of aged mice at 7 days
post fracture [33]. LIPUS treatment led to increases in bone mor-
phogenic proteins BMP-2, BMP-4 and BMP-6 of around 8, 10 and
5-fold higher respectively over controls. This enhanced expression
of BMPs in response to LIPUS has also been reported in a study of
ROS 17/2.8 osteoblastic cells stimulated in 6 well tissue culture
plates [37]. The ultrasound stimulation configuration differed from
previous in vitro studies, in that the cells were stimulated from
above with the transducer touching the surface of the medium,
with the cells 3–4 mm away from the surface of the transducer.
Although the cells were stimulated from above, they were still
within the near ultrasound field. The cells were stimulated with
ultrasound 20 minutes per day for up to 7 days. After 7 days stim-
ulation in culture there were clear increases in protein levels for
BMPs 2, 4 and 7 in the LIPUS treated cells versus control cultures,
as determined by Western blot analysis.
Another role of enhanced vascularity stimulated by the produc-
tion of angiogenic growth factors is in recruiting osteogenic pro-
genitor cells to the fracture site from the systemic circulation. To
evaluate this effect, parabiotic mice were produced by surgically
joining the circulatory systems of two mice, one of which constitu-
tively expressed green fluorescent protein (GFP) in all cells and tis-
sues and a syngeneic wild-type mouse [38]. Femoral fractures were
then created in the wild type (non-GFP) animals and treated with
LIPUS or a sham device for 20 minutes per day for up to 4 weeks.
Any GFP-positive cells in the callus of a wild-type animal would,
by definition, be derived from circulating progenitor cells. At two
and four weeks, animals were euthanized and the number and
localization of GFP-positive cells were assessed. The hard callus
area was significantly greater in the LIPUS group at 2 and 4 weeks
post fracture (p < 0.05), as reported in other studies [25,26,28]. In
addition, a significant increase in alkaline phosphatase positive
cells in the fractures treated with LIPUS at 2 weeks post fracture
was observed (p < 0.05), which complements the increased mRNA
expression of alkaline phosphatase reported in other studies [39].
Fractures treated with LIPUS had significantly more GFP cells, from
the adjacent animals as compared to control fractures, as assessedby histomorphometry, suggesting that LIPUS increased the homing
of the progenitor cells to the fracture site. The authors investigated
the mechanism for the enhanced recruitment of osteogenic pro-
genitors. Confocal micrographs of the fracture site at 2 weeks
showed many CXCR4 positive cells in the LIPUS treated fractures
that were virtually absent in control fractures. CXCR4 is expressed
on the surface of cells and is the receptor for stromal derived factor
1 (SDF-1 or CXCL12) which plays a key role in the recruiting of cir-
culating cells to sites of repair [40,41]. In a separate study [42] the
migration of transplanted mesenchymal stem cells (MSCs) to the
fracture site was investigated by fluorescent imaging. MSCs were
isolated from a rat femur and stimulated with LIPUS for 20 minutes
per day for 3 days. The cells were subsequently injected into rats
with a closed femoral fracture. This study demonstrated that LIPUS
promoted MSC migration to the fracture site, which was associated
with an increase of local and serum SDF-1 level. The in vitro anal-
ysis showed that LIPUS upregulated SDF-1 and CXCR4 expressions
in MSCs. MSCs migration was promoted by LIPUS. Therefore, two
studies independently concluded that LIPUS is having an effect of
increasing the recruitment of cells to the fracture site [38,42].3. Mechanism of action of LIPUS in fracture repair
3.1. Process of LIPUS stimulation
As described earlier the general manner of how LIPUS enhances
fracture repair can be explained by the mode of action. The mode is
the expression of molecules and actions that need to occur in order
to achieve fracture repair, as outlined above. However, to truly
understand the process of how LIPUS influences fracture repair
we must understand the mechanism of action, which is the
description of the events after the signal leaves the transducer,
enters the tissue and initiates key events that lead to fracture
repair.
Work performed on human cadaveric specimens has demon-
strated that the LIPUS signal can produce motion at the fracture
site [43]. An osteotomy was performed on the radius of the cada-
ver, LIPUS applied, and the motion measured using a laser interfer-
ometer. Motion was measured at the proximal and distal edges of
the bone in the osteotomy, while the LIPUS device was activated
(Fig. 1). From these experiments it was found that motion occurred
at a frequency of 1 kHz, matching the pulse modulation of the
LIPUS signal. The interferometer measured velocity amplitude.
Velocity amplitude measurements can be converted to displace-
ment amplitudes using the following equation:
v ¼ A cosxt ¼ A cos½2pft
s ¼
Z
v  dt ¼
Z
A sin½2pft ¼ A
2pf
sin½2pft
where A = velocity amplitude, s = displacement amplitude, f = mea-
surement frequency. When calculated, it was found that at a mea-
surement frequency of 1 kHz, the velocity amplitude of the bone
ends and soft tissue ranged from 1 lm s1 to 3.5 lm s1, equating
to 0.16–0.56 nm displacement, respectively. It is understood that
bone responds to mechanical stimulations and the displacement
is referred to as micromotion. The normal levels of displacement
associated with micro-motion are accepted to be in the range of
0.5–2 mm. Therefore the displacements caused by LIPUS are around
1000 times less than these values, which would suggest that LIPUS
has a different effect on bone compared to micro-motion. Micro-
motion has an anabolic effect on bone mass [44], whereas LIPUS
does not. This difference was demonstrated clinically when patients
suffering from osteoporosis had their distal radius treated daily
with LIPUS for 3 months, and evaluated 3 months after discontinu-
ing the treatment [45]. The results showed that the rate of bone
Fig. 1. The transducer is placed on the skin above the fracture and the low intensity pulsed ultrasound produces nano-motion at the fracture site. The nano-motion is
detected by integrins and the biomechanical wave is converted into a biochemical wave in the cell. One of the main actions in the cell is the production of cyclo-oxygenase 2
or COX2. The enzymatic action of COX2 is the rate limiting step in the production of prostaglandin E2 or PGE2, which is released from the cells and interacts with surrounding
cells through their EP receptors. This action enhances the process of endochondral ossification, which is key for the clinical response.
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density) did not significantly differ between the site treated with
LIPUS and the contralateral control at either 3 months or 6 months
(p = 0.954 and p = 0.410 respectively), suggesting that micro-
motion and nano-motion have different effects.
The EXOGEN device, which produces low intensity pulsed ultra-
sound, was approved by the US Food and Drug Administration in
1994 to accelerate the healing of certain fresh fractures based on
the intensity of 30 mW/cm2 SATA. This intensity of 30 mW/cm2
has been used for all the clinical studies and the majority of pre-
clinical studies when LIPUS has been used. Studies have been per-
formed that have reduced the intensity to see if a threshold could
be detected, below which no biological effect occurred. Rat bone
marrow stromal cells (rBMSC) were recovered from the femurs of
adult animals and cultured in 12 well plates. The culture plates
were placed on an ultrasound transducer array, with the LIPUS
coming from below. The in vitro cell cultures were treated with
ultrasound intensities of 2, 15, and 30 mW/cm2. Alkaline phos-
phatase activitywasmeasured in cells thatwere treated for 20 min-
utes per day for 3, 5, and 7 days and mineral incorporation over a
24 day period. Interestingly, all intensities, even as low as 2 mW/
cm2, showed increases in alkaline phosphatase activity and miner-
alization over the sham control [46]. These data indicate that it is
important for the cells to receive the LIPUS signal, rather than a
specific intensity. The analogy would be similar to a person speak-
ing in a conversation; you can either whisper the message or shout
the message, but as long as the recipient receives the message the
volume is irrelevant. This in vitro conclusion is supported by an
in vivo fracture repair study [47]. Using the closed rat femoral frac-
ture model, the effect of fracture healing of LIPUS treatment at
30 mW/cm2 (approved clinically) and 150 mW/cm2 SATA was eval-
uated by weekly radiographs, micro CT, and biomechanically. The
study concluded that LIPUS at ISATA of 150 mW/cm2 did not further
enhance fracture healing over that of 30 mW/cm2 and was closer to
that of control values compared to that of 30 mW/cm2.
3.2. Conversion of mechanical signal into biochemical signaling
For the ultrasound to have a biological effect, the mechanical
wave must be converted to a biochemical signal within the cell.
The mechano-receptors, integrins, have been implicated in thisprocess. Independent groups have reported activation of integrin
associated signaling pathways through the observation of focal
adhesions forming on the surface of cells treated with LIPUS
[48,49]. Focal adhesions are conglomerations of integrin molecules
which initiate intra-cellular proteins to translocate to inside of the
cell where the intra-cellular components of integrins are found.
There are many components of the intracellular portion of the focal
adhesion that are able to initiate a cell signaling cascade. One of the
key focal adhesion proteins implicated with the transduction of the
LIPUS signal from a mechanical force to a biochemical signal is
focal adhesion kinase (FAK), which is phosphorylated in response
to LIPUS. Several groups have also shown a link between the stim-
ulation of integrins and extracellular signal-regulated kinase (ERK)
signaling in the transmission of LIPUS, which is considered down-
stream of FAK [49,50].
3.3. Downstream effect of biochemical signaling: COX2 in the
mechanism of LIPUS induced fracture repair
From the best available evidence, it is strongly suggested that a
key molecule stimulated by LIPUS through the pathways described
above is cyclo-oxygenase 2 (COX2) [51]. COX2 is the rate-limiting
enzyme in the production of prostaglandin E2 (PGE2). It has also
been demonstrated that LIPUS stimulates prostaglandin H syn-
thase 2 (PGHS-2) expression and PGE2 synthesis [52]. The inhibi-
tion of COX2 by non-steroidal anti-inflammatory drugs (NSAIDs)
has been strongly implicated in impaired fracture repair in both
clinical and pre-clinical studies [53,54]. It is also reported that
older mice produce less COX2, leading to reduced capacity of frac-
ture repair [4]. It is therefore unsurprising that a number of publi-
cations have shown that COX2 is a key molecule stimulated in cells
after the application of LIPUS [50,55]. The secretion of PGE2 was
significantly upregulated over 24 h after a single 20 min applica-
tion of LIPUS [50,55]. One study [50] has linked all aspects of the
signaling described above and associated this to the enhancedmin-
eralization caused by LIPUS. This work demonstrated that LIPUS
was able to increase the levels of integrin expressed on the cell sur-
face (a2, a5, b1 and b5 sub-units). They also showed that LIPUS
caused the phosphorylation of FAK, which led to the phosphoryla-
tion of the p85 sub-unit of phospho-inositol 3 kinase (PI3K), then
the phosphorylation of AKT, and finally the translocation of the
50 A. Harrison et al. / Ultrasonics 70 (2016) 45–52p65 subunit of NF-jb to the nucleus. At each stage of this pathway,
when inhibitors were used, the enhanced COX2 production was
ablated, strongly suggesting that this intra-cellular pathway is
stimulated by LIPUS to initiate the production of COX2. These
results were corroborated using a COX2 luciferase assay which,
after the treatment with LIPUS, significantly increased this activity
compared to non-treated controls. When these LIPUS stimulated
cells were treated with either chemical pathway inhibitors or dom-
inant negative mutant forms of FAK, PI3K, AKT or ERK, the activity
of the COX2 was significantly reduced. Finally, it was demonstrated
that, via this pathway, LIPUS could enhance the mineralization of
osteoblastic cells. This enhanced mineralization stimulated by
LIPUS could be significantly ablated when the cultures were trea-
ted with dominant-negative mutant forms of FAK, PI3K or AKT.
However, the most compelling evidence that the stimulation by
LIPUS through this pathway activates COX2 was shownwhen these
cultures were treated with NS-398, a COX2 inhibitor. Again the
enhanced mineralization caused by LIPUS was significantly
reduced. This evidence strongly implicates the LIPUS signal is
transduced through these specific pathways in the cell, which
leads to the production of COX2 and drives mineralization in stim-
ulated osteoblasts.
In vitro cell biology experiments, especially in cells of estab-
lished cell lines, can only explain so much, and the mechanism of
COX2 activation was verified in an in vivo model. In femur frac-
tures of standard aged (one year old) wild type mice, stimulation
with LIPUS showed an enhanced healing response compared to
untreated contralateral controls, as previously discussed. However,
in animals where COX2 had been knocked out, fracture healing via
histology was undistinguishable compared to controls. These
results demonstrate that the production of COX2 is essential for2. Signal activates 
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Fig. 2. As the pressure wave comes through the tissues it interacts with cells and is de
transcription of genes in the nucleus, the main activation is in the transcription of CO
prostaglandin E2 which is released from the cells to have the clinical effects.the induction of gene transcription for both osteogenesis and
remodeling, and thereby for the enhanced fracture repair stimu-
lated by LIPUS [33]. In a study of alveolar bone defect as a result
of molar tooth removal in rats, involvement of humoral PGE2,
which was released from the site of LIPUS stimulation via upregu-
lated COX2, was suggested in the de novo expression of CXCR4 in
the remote bone marrow in tibia [56].
COX2 is associated with the initiation of inflammatory
responses by producing prostaglandins. PGE2 stimulates osteoclast
formation by increasing RANKL mRNA expression via cAMP-
protein kinase A (PKA) pathways in osteoblasts. Therefore, a timely
COX2 induction by LIPUS inevitably accelerates callus remodeling
from cartilage and woven bone into lamellar bone to restore the
cortical bone. The activation of resorbing cells (osteoclast and
chondroclast) is supported by the increased RANKL expression,
both at the protein and mRNA levels in established cell lines and
osteoblastic cells [57,58]. Inflammatory conditions may activate
multiple pathways in inflammasome preparation as a first step
priming through toll-like receptors and TNF or IL-1b receptors that
also activate NF-kB [59].4. Summary
LIPUS waves cause nanomotion at the fracture site. Themechan-
ical signal is converted to a biochemical signal inside the cells and is
ultimately transmitted through signaling molecules to drive the
production of COX2 in the cell. This cascade requires the involve-
ment of integrins and the formation of focal adhesions. The
enhanced COX2 stimulation, likely through the production of
PGE2, drives the expression of osteogenic genes. These osteogeniceus
e
OX2) 
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constructed by 
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6. PGE2 
produced 
by the cell 
providing 
the clinical
effect.
tected by integrins. Multiple pathways are initiated in the cell which leads to the
X2. The mRNA of COX2 is converted to protein that then produces the eicosanoid
A. Harrison et al. / Ultrasonics 70 (2016) 45–52 51genes stimulate enhanced mineralization, which is seen as
enhanced endochondral ossification that heals the fracture (Fig. 2).
This enhanced mineralization caused by LIPUS can be observed in
cell culture experiments [35,36,50], in vivomodels of fracture repair
[25,26,33] and in clinical trial data [60].5. Conclusion
Many intensities and frequencies have been evaluated, but the
greatest number of clinical and pre-clinical studies have used a sig-
nal comprised of 30 mW/cm2 ISATA, an ultrasound frequency of
1.5 MHz and pulsed at 1 kHz. It is this signal that was used in
the level-I clinical studies demonstrating acceleration of fracture
repair in diaphyseal tibial fractures and distal radial fractures
respectively [12,13]. Studies have also demonstrated that this sig-
nal is highly efficacious in the treatment of recalcitrant non-union
fractures [14,16].
A search of the PubMed database of LIPUS finds over 250 arti-
cles. However, most articles generally state that the underlying
mechanism of action remains unclear. From the data presented
here, we hope to convince the reader that there is a rich literature
in the science of LIPUS and that these articles indicate that there is
a robust mode and mechanism behind the LIPUS technology.
It is commonly understood that fracture repair can be described
as different phases. These phases include inflammatory, intramem-
branous ossification, chondrogenesis, endochondral ossification
and finally remodeling. It is not clear at this time exactly which
types of cells are involved in each phase; however it has been
demonstrated that LIPUS can have positive effects in all these
phases [25].
The central molecule in this proposed mechanism of action is
cyclo-oxygenase 2 (COX2), the key enzyme in the production of
prostaglandins. Prostaglandins have been shown to play an impor-
tant role in bone fracture repair [53,54]. This evidence could indi-
cate, therefore, that stimulating COX2 might be a good attribute for
fracture repair. Studies have shown a positive effect on COX2 and
PGE2 levels in response to LIPUS [50,55]. However, the most com-
pelling evidence of this was the near total lack of efficacy of LIPUS
in the aged COX2 knockout mouse, which strongly implies that
COX2 sits centrally in the mechanism of action of LIPUS [33].
In conclusion, we have set out in this paper to demonstrate that
within the scientific literature there is evidence that suggests a
mechanism of action of how LIPUS stimulates fracture repair. We
have illustrated how the signal is transmitted through tissue to
the fracture site, how the bone at the fracture site is made to move
at the nano-meter range, and how cells are able to sense this signal
by forming focal adhesions. We have shown how signaling path-
ways are initiated within the cell and how COX2 is produced lead-
ing to increased production of PGE2, which when blocked
correlates to a lack of effect of LIPUS in enhanced fracture repair.
The LIPUS signal has had a long history of safe and efficacious
use and with continuing investigation more information will be
generated in how this technology can stimulate the healing of
tissues.
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